Publications by authors named "Allison M Winter"

Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated with mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI therapy efficacy more definitively in this population, we retrospectively evaluated clinical outcomes in a large cohort of 96 patients with aggressive B-cell lymphomas receiving CPI therapy after CAR-T failure across 15 US academic centers. Most patients (53%) had diffuse large B-cell lymphoma, were treated with axicabtagene ciloleucel (53%), relapsed early (≤180 days) after CAR-T (83%), and received pembrolizumab (49%) or nivolumab (43%).

View Article and Find Full Text PDF

Previous studies have demonstrated low rates of seroconversion to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients with chronic lymphocytic leukemia (CLL). In this national collaboration of 11 cancer centers in the United States, we aimed to further characterize and understand vaccine-induced immune responses, including T-cell responses, and the impact of CLL therapeutics (#NCT04852822). Eligible patients were enrolled in 2 cohorts (1) at the time of initial vaccination and (2) at the time of booster vaccination.

View Article and Find Full Text PDF

Introduction: Polatuzumab vedotin is approved therapy in the United States for relapsed/refractory diffuse large B-cell lymphoma in combination with bendamustine and rituximab (Pola+BR). However, the safety and efficacy of Pola+BR outside of a clinical trial setting is unknown.

Patients And Methods: We analyzed use of pola-based therapy at 5 centers in the United States, including dose, response rates, progression-free survival (PFS), survival, and toxicity.

View Article and Find Full Text PDF

Data on real-world outcomes of axicabtagene ciloleucel (axi-cel) therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL) are limited. In this intent to treat (ITT) analysis, we reviewed records of 38 consecutive patients with R/R LBCL for whom axi-cel was intended. Twenty-seven (71%) patients received axi-cel and 11 (29%) did not.

View Article and Find Full Text PDF
Article Synopsis
  • Venetoclax-based therapy is a standard treatment for chronic lymphocytic leukemia (CLL), but how to manage patients after stopping it is unclear.
  • A study involving 326 patients who discontinued venetoclax explored their responses to different treatments, focusing on overall response rate and progression-free survival.
  • Results indicated that BTK inhibitors were highly effective for patients who had not previously received them, while less effective for those who had, and PI3K inhibitors provided limited benefit, highlighting the importance of treatment history when selecting post-venetoclax therapies.
View Article and Find Full Text PDF
Article Synopsis
  • * A study compared 321 patients across the U.S. and U.K., analyzing demographics, treatment responses, and survival outcomes for both treatment approaches.
  • * Results showed similar overall response rates and no significant differences in progression-free or overall survival between VENmono and VENcombo, suggesting both treatments are equally effective, though further studies are necessary for confirmation.
View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated the occurrence of tumor lysis syndrome (TLS) and adverse events (AEs) in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax outside of clinical trials, involving 297 patients from various treatment centers.
  • - Among the findings, only 2.7% of patients experienced clinical TLS and 5.7% had laboratory TLS, with major adverse events including neutropenia and thrombocytopenia being notable.
  • - The results suggest a need for better TLS risk grading and prophylaxis adherence in routine practice, despite progression-free survival being unaffected by dose modifications in this patient group.
View Article and Find Full Text PDF

The B-cell receptor signaling pathway is active in diffuse large B-cell lymphomas, with increased expression of MYC and BCL2 protein. The overall response rate was 60% for relapsed/refractory non–germinal center double-expressor lymphoma patients treated with ibrutinib.

View Article and Find Full Text PDF

Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL, resulting in disparate practice patterns. Prospective trials have shown benefit of MR after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or R-CVP (rituximab, cyclophosphamide, vincristine, prednisone), yet recent data from the GALLIUM study comparing outcomes of patients treated with chemotherapy with R or obinutuzumab (G) showed higher than anticipated fatal adverse events with BR/BG.

View Article and Find Full Text PDF
Article Synopsis
  • Venetoclax is a BCL2 inhibitor used to treat chronic lymphocytic leukemia (CLL) patients with specific genetic mutations, showing effectiveness even after previous kinase inhibitor treatments.
  • A study of 141 CLL patients revealed a 72% overall response rate to Venetoclax, with common side effects including neutropenia and thrombocytopenia, but many patients reached the maximum recommended dosage.
  • Further research is needed to determine the best order for using newer CLL therapies, as many patients successfully transitioned to other treatments like ibrutinib after stopping Venetoclax.
View Article and Find Full Text PDF